High levels of circulating GM-CSF + CD4 + T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study

Huihuang Huang,Siyu Wang,Tianjun Jiang,Rong Fan,Zheng Zhang,Jinsong Mu,Ke Li,Yonggang Wang,Lei Jin,Fang Lin,Jie Xia,Lijian Sun,Biao Xu,Chengcheng Ji,Jing Chen,Juan Chang,Bo Tu,Bing Song,Chao Zhang,Fu-Sheng Wang,Ruonan Xu

DOI: https://doi.org/10.1038/s41423-018-0164-2

2018-01-01

Abstract:Granulocyte colony-stimulating factor (GM-CSF), produced by CD4 + T cells, has recently been implicated in the pathogenesis of inflammatory diseases, such as multiple sclerosis and juvenile arthritis. However, the role of GM-CSF-producing CD4 + T cells in sepsis remains unknown. This study reports peripheral changes in GM-CSF-producing CD4 + T cells in septic patients and the possible underlying mechanism by which GM-CSF influences the outcome of sepsis. Forty-three septic patients, 20 SIRS patients, and 20 healthy controls were enrolled in this study and followed for 28 days to assess mortality. We measured the peripheral frequency of GM-CSF + CD4 + T cells and recorded their associated relationship with disease progression. Our data demonstrated that peripheral GM-CSF-producing CD4 + T cells were significantly higher in septic patients than in both SIRS patients and healthy controls. These cells exhibit a memory phenotype and impaired IFN-γ-secreting capacity in sepsis patients. Using a receiver operating curve analysis with 8.01% as a cut-off point, the percentage of GM-CSF + CD4 + T cells could predict the outcome of septic patients . Combined with the increase in GM-CSF-producing CD4 + T cells, inflammatory cytokines IL-1β and IL-6 were also upregulated. Using an in vitro neutrophil model, we found that GM-CSF inhibited C3aR expression, while inducing IL-8 production. Furthermore, this effect was transferrable in plasma from sepsis patients and was attenuated by inhibition of GM-CSF using an anti-GM-CSF antibody. These results indicate that GM-CSF-producing CD4 + T cells may serve as a marker of sepsis severity. Thus, targeting GM-CSF overproduction may benefit sepsis patients.